指南与共识造血干细胞移植与细胞治疗血栓与止血

替沙仑赛CAR-T治疗后凝血病监测与管理的实践指南

Practical guidelines for monitoring and management of coagulopathy following tisagenlecleucel CAR T-cell therapy.
指南 / 共识 · Blood Adv · 2021-01-01

基于ELIANA和ENSIGN试验中137例复发/难治B细胞急性淋巴细胞白血病患者,总结替沙仑赛治疗后细胞因子释放综合征(CRS)相关凝血病的监测与管理经验。低纤维蛋白原血症仅见于重度CRS患者,采用纤维蛋白原浓缩物或冷沉淀替代治疗可有效管理,严重出血事件罕见。指南强调中重度CRS患者需监测纤维蛋白原水平。

要点

  • 低纤维蛋白原血症仅发生于重度CRS患者,需监测纤维蛋白原水平。
  • 纤维蛋白原<1.5 g/L时需替代治疗,<1 g/L为显著低纤维蛋白原血症。
  • 无冷沉淀时可用纤维蛋白原浓缩物替代,严重出血事件罕见。

核心结论

  • CRS相关低纤维蛋白原血症可根据经验性纤维蛋白原替代指南进行管理。
  • 中重度CRS患者监测纤维蛋白原水平对避免致命性出血至关重要。

研究设计与样本

  • 基于ELIANA和ENSIGN两项试验的全球多中心经验,纳入137例复发/难治B细胞急性淋巴细胞白血病患者。
  • 试验包含CRS相关凝血病期间纤维蛋白原替代的临床指南。

主要发现

  • 需替代治疗的低纤维蛋白原血症仅见于重度CRS患者。
  • 需替代治疗的患者中<10岁比例高于无需替代者。
  • 纤维蛋白原<1 g/L见于最大CRS前(n=1)、最大CRS期间(n=7)和CRS改善时(n=1)。
  • 部分患者还出现凝血酶原时间延长、活化部分凝血活酶时间延长和国际标准化比值升高,增加出血风险。

关键数值与推荐

  • 低纤维蛋白原血症定义为<1.5 g/L时需替代治疗,<1 g/L为显著低纤维蛋白原血症。
  • 纤维蛋白原浓缩物或冷沉淀用于替代治疗;冷沉淀不可靠时可使用纤维蛋白原浓缩物。
  • 严重(4级)出血事件罕见(n=2)。

临床怎么用

  • 对中重度CRS患者应监测纤维蛋白原水平。
  • 纤维蛋白原<1.5 g/L时启动替代治疗,优先使用冷沉淀,不可靠时用纤维蛋白原浓缩物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cytokine release syndrome (CRS) is a systemic inflammatory response associated with chimeric antigen receptor T-cell (CAR-T) therapies. In severe cases, CRS can be associated with coagulopathy and hypofibrinogenemia. We present our global multicenter experience with CRS-associated coagulopathy after tisagenlecleucel therapy in 137 patients with relapsed or refractory B-cell acute lymphoblastic leukemia from the ELIANA and ENSIGN trials. These trials included clinical guidelines for fibrinogen replacement during CRS-associated coagulopathy. Hypofibrinogenemia requiring replacement was observed only in patients with severe CRS. A higher percentage of patients who required replacement were <10 years old, compared with those who did not require replacement. Twenty-three patients received replacement for hypofibrinogenemia (<1.5 g/L); 9 of them developed marked hypofibrinogenemia (<1 g/L). Very low fibrinogen levels (<1 g/L) were documented in patients before maximal CRS (n = 1), during maximal CRS (n = 7), and at CRS improvement (n = 1). Although hypofibrinogenemia was the most clinically significant coagulopathy, some patients also developed prolonged prothrombin time and activated partial thromboplastin time and increased international normalized ratio, further increasing the risk of bleeding. Hypofibrinogenemia was effectively managed using fibrinogen concentrate or cryoprecipitate replacement; severe (grade 4) bleeding events were rare (n = 2). CRS-associated coagulopathy with hypofibrinogenemia is manageable according to empiric guidelines of fibrinogen replacement for CAR-T trials. Fibrinogen concentrate should be used when cryoprecipitate is not reliably available. Monitoring fibrinogen levels in patients with moderate or severe CRS is essential for avoiding potentially fatal bleeding events. These trials were registered at www.clinicaltrials.gov as #NCT02435849 and #NCT02228096.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Buechner J, Grupp SA, Hiramatsu H, et al. Practical guidelines for monitoring and management of coagulopathy following tisagenlecleucel CAR T-cell therapy. Blood Adv. 2021. PMID: 33496754. doi:10.1182/bloodadvances.2020002757

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。